-
May 19, 2022 Non RegulatoryUmecrine Cognition submits application for Phase 2 clinical trial of golexanoloneSTOCKHOLM – May 19, 2022. Umecrine Cognition AB today announces that the company has submitted a clinical trial application (CTA) for a Phase 2...
-
May 18, 2022 Non RegulatoryNotice to attend the Annual General Meeting in Umecrine Cognition ABThe shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend the annual general meeting at 10:00 a.m. on Friday...
-
March 14, 2022 Non RegulatoryUmecrine Cognition completes successful pre-IND meeting with FDASTOCKHOLM – March 14, 2022. Umecrine Cognition AB today announces that the company has completed a pre-IND meeting with the U.S. Food and Drug...
Subscribe
Our drug projects
GABAA receptor modulating steroid antagonists: our scientific focus
Our lead product candidate, golexanolone, is a novel small molecule GABAA receptor-modulating steroid antagonist in development for the treatment of neurological disorders caused by overactivation of GABA-A receptors by the neurosteroid allopregnanolone.